Bristol Myers Squibb Q3 EPS falls to $1.05; revenue rises 7% to $13.07 billion
BMY•Bristol Myers Squibb reported third-quarter 2026 GAAP EPS of $1.05, down year over year, while revenue rose 7% to $13.07 billion.
BMY•BMY•BMY•Bristol Myers Squibb reported third-quarter 2026 GAAP EPS of $1.05, down year over year, while revenue rose 7% to $13.07 billion.
Bristol Myers Squibb’s third-quarter 2026 GAAP earnings per share fell to $1.05, while total revenues rose 7% year over year to $13.07 billion. GAAP gross margin narrowed 3.6 percentage points to 68.3%, primarily due to a change in product mix. Acquired IPRD charges more than doubled to $1.56 billion, primarily reflecting recent license agreements and ongoing collaborations. Zenbexus received FDA approval for previously treated adults with multiple myeloma.
